Company / Accounts Receivable
GeneDx Holdings Corp. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$74.4M
FY2025
5-year range
$26.5M / $74.4M
FY2021-FY2025
Trend
+97.6%
vs FY2024
Sector context
#111 of 143
Health Care
What the data says
GeneDx Holdings Corp.'s accounts receivable of $74M is lower than 78% of companies in the Health Care sector (FY2025). Accounts Receivable has fluctuated over the past 5 years, ranging from $27M in FY2021 to $74M in FY2025.
Based on SEC 10-K filings.
$74M in FY2025 with a 5-year CAGR of +18.3%.
Improved from $43M to $74M over the past 3 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +20.4%
- 5-Year CAGR
- +18.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 143This company $74.4M Sector average $1.3B
▼
-94.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 97.6% year-over-year.
- Ranks #111 out of 143 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.4M | +97.6% |
| FY2024 | $37.6M | - |
| FY2023 | - | - |
| FY2022 | $42.6M | +60.8% |
| FY2021 | $26.5M | -17.3% |
| FY2020 | $32.0M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026